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My colleagues and I were honoured to have so many reputable scholars taking precious time to read our article1 and write three solid commentaries.2-4 
We were flattered by their positive remarks and respectfully 
pondered the weaknesses and omissions their commentaries 
underlined. In this response, we wish to provide some 
background to the program of research our article synthesised 
and reflect on ways to consolidate further research on the 
value of innovation, which indeed remains a “bright elusive 
butterfly.”2 
When we developed a decade ago our research program, we 
had a hard time to convince our peers that such research 
was feasible and that it would, ultimately, bring a relevant 
contribution to health services and policy research. No matter 
the topic, it is never easy to obtain peer-reviewed funding. Yet, 
the additional difficulties we faced later when it was time to 
publish our findings revealed how tricky it is, in practice, to 
cross disciplinary boundaries and address the “big picture” of 
innovation in health, which entails understanding how the 
“supply” works. 
On the one hand, when we submitted our findings to journals 
whose audience were entrepreneurship and innovation policy 
scholars, we were told that the “health” implications we were 
seeking to tackle were not important: what really mattered 
amounted to the entrepreneurial dynamics that supported or 
hindered the production of innovation. On the other hand, 
when we submitted our findings to journals whose audiences 
were health services and policy scholars, we were told that 
the business and financial dynamics we were describing were 
alien to health policy: what really mattered was examining the 
impact of innovation utilisation. 
When we received constructive criticisms (and also praise) 
from six reviewers on what we considered the last piece of 
our research program we were thus at a loss. A quizzical yet 
gratifying kind of loss. What happened in the past decade that 
now makes our research relevant and timely in the eyes of our 
peers?
One observation by Greenhalgh et al2 sheds some light on 
this question. Throughout their fieldwork on electronic 
patient records and assisted living technologies that spanned 
several years, they noticed an emerging “radical change in the 
strategy taken by large technology companies” to developing 
new health technologies. Companies such as Microsoft, 
Tunstall and Philips would show an increasing willingness to:
engage in long-term strategic partnerships with health 
and social care organisations, promote open standards, 
data exchange and interoperability in ways that facilitate 
collaboration across suppliers and increase potential for 
widespread adoption, undertake ethnographic studies and 
co-design projects, and hire clinical staff with extensive 
patient-facing experience. 
The information technology (IT) sector does indeed open up 
new ways of designing and bringing new technology to market. 
It also calls for significant changes in established regulatory 
processes and reimbursement systems. While the broader 
medical device industry will not be swiftly transformed by 
the new IT-based ways of doing business, there is a different 
breed of entrepreneurs with whom health services and 
policy researchers could productively collaborate. Similarly, 
Buttigieg and van Hoof3 stress that the design of innovation 
should mobilise to a greater extent the professional values of 
clinician-entrepreneurs. Clinicians who anticipate usability, 
ethical, social and cultural issues and enterprises that show 
a genuine interest in addressing system-level challenges do 
in fact contribute to increase the relevance and timeliness of 
research on the production of innovation.5 
The model created by Greenhalgh and colleagues that 
expands our own framework to embrace additional sources 
of influence forms an excellent basis to pursue research 
on the value of innovation. Within this perspective, one 
methodological lesson that we would like to share is not to 
overstate the difficulty of doing research with entrepreneurs 
and investors. It is of course challenging because ventures are 
small enterprises that struggle with steady growth, multiple 
pressures and commercial secrecy issues. Nevertheless, the 
entrepreneurs and investors we interviewed were surprised 
and thrilled that “health folks” showed interest in their work 
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and ways of thinking. They were eager to share with us their 
knowledge and genuinely voiced their impressions about 
what required improvements in the innovation ecosystem. In 
return, our analyses took their business concerns seriously; 
that is, we carefully sought to identify the rules of the game 
that condition how they think, what they value and how they 
handle power relations. 
As our article showed, the “butterfly” that clinician-
entrepreneurs chase entails a double promise wherein the 
innovation must come with a profitable business model and 
generate health benefits. The “butterfly” investors chase 
is speculative; how much and how fast can a new venture’s 
economic value grow and generate returns? This is in contrast 
with the “butterfly” chased by regulators for whom value 
requires evidence of safety and efficacy (in the case of high-
risk devices) and of the legal auditability of its manufacturer. 
While it is not part of the regulatory agencies’ mandate to 
consider the relevance of an innovation and its economic 
implications, these agencies provide economic worth to the 
ventures that obtain market approval. Hence, by learning 
how to chase butterflies, we were able to show that those who 
invest in ventures extract economic value from the regulatory 
process, an important lesson considering that regulatory 
requirements are typically characterized as hindering the 
innovation process.
As Parvizi and Parvizi4 underscore, policy-oriented initiatives 
that build on health technology assessment (HTA) may 
increase, at an early stage, the circulation of information 
between technology developers and health decision-makers. 
For instance, the National Institute for Health and Care 
Excellence (NICE) in the United Kingdom “have a dedicated 
process for selecting technologies identified” by the National 
Institute of Health Research Horizon Scanning Centre and 
“are informed of new drugs in development 20 months ahead 
of marketing authorisation.”5 Yet, these authors also stress that 
a more comprehensive health innovation policy is needed, one 
that entails the “development and maintenance of a resilient 
and adaptable infrastructure so that the healthcare system is 
not overwhelmed by new technologies” and on innovation 
performance measures to “guide future advances.” We 
could not agree more and invite both health and innovation 
policymakers to add to their must-read list the review of 
Nightingale and Coad on the political and methodological 
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